Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2– Advanced or Metastatic Breast Cancer: A US Payer Perspective

Overview of attention for article published in Frontiers in Medicine, June 2021

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 16 Dimensions

Readers on

mendeley: 26 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 16 publications that cite this research output.

16

The most recent citing publications are shown below. View all 16 publications that cite this research output on Dimensions.

Cost-effectiveness of early vs delayed use of abemaciclib combination therapy for patients with high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer.

Article in Journal of Managed Care & Specialty Pharmacy (September 2024)

Comparative cost-effectiveness analysis of CDK4/6 inhibitors in the first-line treatment of HR-positive and HER2-negative advanced breast cancer: a Markov's model-based evaluation

Article in Frontiers in Oncology (July 2024)

Is circulating tumor cell count-driven cost-effective for first-line therapy choice in HR+/HER2- metastatic breast cancer in the United States?

Article in The Breast (February 2024)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.